Tagged with B

Portugal Graca Didier, secretary general of AmCham Portugal, discuss the role of her chamber of commerce in promoting strong relations between America and Portugal. In addition, she comments on the cultural differences between the two countries and how Portugal can learn a lot from America in terms of creating a better…

China The Greater Bay Area (several cities in Guangdong Province in mainland China along with Hong Kong and Macau) is a major Chinese government scheme to link the entire region into an integrated economic and business hub . The Greater Bay Area, taken as a whole, dwarfs the world’s other major…

UK Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international collaboration and Brexit.     Most likely, the UK is the best environment for putting forward trials that are properly…

Canada Referring to the Canadian affiliate of Zimmer Biomet as a “trailblazer”, Dave O’Neil looks back on a successful 2017 for the musculoskeletal healthcare company in Canada. He describes how Zimmer Biomet positions itself as a true partner in driving efficiency in the Canadian healthcare system. 2017 was an eventful year…

Baltics In terms of being able to access medicines, patients in the Baltic states fare poorly compared to many of their European counterparts. 135 new medicines were approved by regulators in Lithuania and Estonia in 2016, but only 38 and 30 were made available to patients respectively. Latvia fares even worse,…

Latvia The top 20 companies in the Latvian pharmaceutical market for 2017, sorted by total value and market share, with data on year-on-year growth. American giant AbbVie ranks first, with an almost six percent market share and astounding 65 percent year-on-year growth, followed by TEVA and Sanofi.

UK Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs. How would you describe Biogen’s…

UK Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the highlights of his tenure in terms of medical research in the UK, and the potential pitfalls of the Brexit process.…

India The global pharmaceutical outsourcing market was estimated to be USD 115.7 billion in 2016, of which 49 percent is accounted for by contract research organisations (CROs). Within India, the contract research market is scheduled to grow from around USD one billion in 2016 to USD 1.97 billion by 2023 according…

UK Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why the UK will remain a leading research hub in the years to come.   One of our key challenges is…

Canada Despite its relative youth, Canada’s medical cannabis industry is already presenting some of the characteristics of the much more mature pharmaceutical industry. There is consolidation as well as the first moves towards differentiating business models. “With medical cannabis, there is a chance to re-evaluate entirely the way we look at…

India In this exclusive interview, Binish Chudgar, vice-chairman and managing director of Intas, the largest privately-owned Indian pharmaceutical company with sales of over USD 1.7 billion during the last financial year, provides insights into the company’s growth model and M&A approach, as well as his objectives with regards to a large-scale…